Bioequivalence Study of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects

The primary objective of this study is to evaluate the **bioequivalence** of an Etonogestrel 68 mg implant in healthy pre-menopausal, nonpregnant female subjects. This assessment is clinically relevant as it determines whether the new formulation of the implant delivers the same therapeutic effect as the existing standard, ensuring consistent efficacy and safety for contraceptive use. No secondary objectives are specified for this study.

The clinical trial involves a **study population** consisting exclusively of female participants, with an age range categorized as 3, which typically corresponds to a specific age group as defined by the trial's criteria. The trial does not focus on any specific **medical condition**, indicating that participants are generally healthy or do not have a targeted disease. The trial population includes a vulnerable group, suggesting additional ethical considerations in the study design. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial's focus on a vulnerable population highlights the importance of careful monitoring and ethical oversight throughout the study.

The clinical trial is designed to evaluate the **bioequivalence** of an etonogestrel 68 mg implant in healthy pre-menopausal, nonpregnant female subjects. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is June 2, 2023, with an anticipated end date of November 5, 2023, indicating a total trial duration of approximately five months. Participants will be involved in the study for the entire duration unless specific conditions necessitate early termination, such as adverse reactions or non-compliance with study protocols.

The sequence of study visits begins with an inclusion (screening) visit, where eligibility criteria are assessed to ensure participants meet the necessary requirements for trial participation. Following successful screening, participants will undergo a series of follow-up visits at predetermined intervals to monitor the implant's bioequivalence and any potential side effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed on the study's outcomes. Throughout the trial, adherence to the protocol is essential, and any deviation may result in early withdrawal from the study.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on June 2, 2023, with an estimated end date of November 5, 2023. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial's focus is on evaluating the efficacy of the intervention within the defined trial phase and category.